- document
-
van de Haar, Joris (author), Mankor, Joanne M. (author), Hummelink, Karlijn (author), Monkhorst, Kim (author), Smit, Egbert F. (author), Wessels, L.F.A. (author), Cuppen, Edwin (author), Aerts, Joachim G.J.V. (author), Voest, Emile E. (author)PURPOSE: The clinical value of STK11, KEAP1, and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed for this...journal article 2024
- document
-
van de Haar, Joris (author), Ma, Xuhui (author), Ooft, Salo N. (author), van der Helm, Pim W. (author), Hoes, Louisa R. (author), Mainardi, Sara (author), Pinato, David J. (author), Sun, Kristi (author), Wessels, L.F.A. (author)Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified KRAS codon G12 (KRAS...journal article 2023
- document
-
de Vries, Natasja L. (author), van de Haar, Joris (author), Veninga, Vivien (author), Chalabi, Myriam (author), Ijsselsteijn, Marieke E. (author), van der Ploeg, Manon (author), van den Bulk, Jitske (author), Ruano, Dina (author), Wessels, L.F.A. (author)DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)<sup>1,2</sup>. Here, in contrast to other cancer types<sup>3–5</sup>, we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactivation of β2-microglobulin ...journal article 2023